Abstracts Archive - Page 1580 of 2425 - ACR Meeting Abstracts

Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting
Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Emily Fishman¹, Kathryn H. Dao² and John J. Cush³, ¹Texas A&M HSC College of Medicine, Dallas, TX, ²Texas Health, Dallas, TX, ³Baylor Research Institute, Dallas, TX
Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
Abstract Number: 2445 • 2016 ACR/ARHP Annual Meeting
Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis
Gopika Miller¹, Elizabeth Moore², Antonia Valenzuela³, Lorinda Chung⁴ and Victoria P. Werth⁵, ¹Medicine, Harbor UCLA Medical Center, Torrance, CA, ²Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁵Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The effect of pregnancy on Dermatomyositis (DM) disease activity and on maternal and fetal outcomes in patients with DM is unclear. Study objective is…
Abstract Number: 2446 • 2016 ACR/ARHP Annual Meeting
Infantile Hemangiomas in Infants Born to Women with Autoimmune Diseases
Chelsey Forbess Smith¹, Kenneth L Jones², Diana L Johnson² and Christina D Chambers², ¹University of California San Diego Department of Rheumatology, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: Infantile Hemangiomas (IH) are the most common benign vascular tumor in infants, estimated to occur in 4-5% of the general population. Many of the…
Abstract Number: 2447 • 2016 ACR/ARHP Annual Meeting
Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar⁴, Ardella Magee⁵, Joel Ager⁶ and Robert Sokol⁷, ¹Internal Medicine, Wayne State University School of Medicine, Detroit, MI, ²Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, ⁵Clinical and Translational Research Center, Wayne State University, Detroit, MI, ⁶Family Medicine, Wayne State University School of Medicine, Detroit, MI, ⁷Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI
Background/Purpose: Cervical neoplasia is increased in women with SLE. HPV types 16 & 18 account for 70% of cervical cancer. Natural HPV cervical infection generates…
Abstract Number: 2448 • 2016 ACR/ARHP Annual Meeting
Contraceptive Methods in Women with Rheumatoid Arthritis
Megan E. B. Clowse, Gary McDaniel and Amanda M. Eudy, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Women with rheumatoid arthritis (RA) often take medications to control disease activity that, should a woman become pregnant, may increase the risk of poor…
Abstract Number: 2449 • 2016 ACR/ARHP Annual Meeting
Infertility in Women with Rheumatoid Arthritis
Megan E. B. Clowse, Gary McDaniel and Amanda M. Eudy, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) is a rheumatic disease that can affect women of reproductive age, and data suggest infertility is increased in RA. The objective…
Abstract Number: 2450 • 2016 ACR/ARHP Annual Meeting
Do Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Have Reduced Fertility and Parity? a Systematic Review
Claire-Louise Murphy¹, Harriet Sharp², Hanh Nguyen³, Anisur Rahman¹ and Ian Giles⁴, ¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, University College London, London, United Kingdom, ³Rheumatology, University College London Hospital, London, United Kingdom, ⁴Department of Rheumatology, University College London Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) often affect women of reproductive age. It remains unclear as to whether these inflammatory rheumatic conditions…
Abstract Number: 2451 • 2016 ACR/ARHP Annual Meeting
Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus
Yonit Sterba¹, Tamara Tanner² and Dawn Wahezi¹, ¹Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, The Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: The onset of childhood systemic lupus erythematosus (cSLE) most frequently occurs after age 12. Studies in adolescents with cSLE suggest that ovarian dysfunction may…
Abstract Number: 2452 • 2016 ACR/ARHP Annual Meeting
Reduced Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients
Renato B. B. Tomioka¹, Gabriela R.V. Ferreira², Nadia E Aikawa³, Gustavo A.R. Maciel¹, Paulo C. Serafini¹, Edmund C. Baracat¹, Cláudia Goldenstein-Schainberg⁴, Rosa M R Pereira⁵, Eloisa Bonfá⁶ and Clovis A Silva², ¹Discipline of Gynecology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ⁶Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Juvenile idiopathic arthritis (JIA) occurs during reproductive age and therefore ovarian reserve and future fertility are a relevant issue for this population. There is,…
Abstract Number: 2453 • 2016 ACR/ARHP Annual Meeting
The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices
Megan E. B. Clowse¹, Amanda M. Eudy², Bonnie L. Bermas³, Eliza Chakravarty⁴, Lisa R. Sammaritano⁵ and Christina D. Chambers⁶, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Edmond, OK, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Pediatrics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are presently no official guidelines about the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro antibodies. The objective…
Abstract Number: 2454 • 2016 ACR/ARHP Annual Meeting
Cohort of Pregnant Women with Ro/La Antibodies: Risk of Fetal Third Degree Atrioventricular Block and Use of Hydroxychloroquine
Florencia Beatriz Mollerach¹, Marina Scolnik², Luis J. Catoggio² and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: Third degree atrioventricular block(AVB), a rare congenital complication, duplicate-triplicate frequency up to 2% when Ro/La maternal antibodies are present. Incidence rises to 17-20% in…
Abstract Number: 2455 • 2016 ACR/ARHP Annual Meeting
Transcriptome Profile of Cells Isolated from a CHB Heart Support an Exuberant Inflammatory ⁄Pro-Fibrotic Cascade
Robert M Clancy¹, Andrew Markham², Tanisha A. Jackson³, Sara Rasmussen¹, Miki Blumenberg⁴ and Jill P. Buyon², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Medicine, NYU School of Medicine, New York, NY, ⁴Dermatology, NYU School of Medicine, New York, NY
Background/Purpose: Histologic correlates of anti-Ro associated congenital heart block (CHB) are apoptosis and calcification of cardiomyocytes with fibrosis of the AV node surrounded by infiltrating macrophages…
Abstract Number: 2456 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Cecilia B. Chighizola², Teresa Del Ross³, Maria Gerosa⁴, Anna Kuzenko³, Maria Gabriella Raimondo⁴, Andrea Lojacono⁵, Sonia Zatti⁵, Francesca Ramazzotto⁵, Laura Trespidi⁶, Pier Luigi Meroni⁷, Vittorio Pengo³, Amelia Ruffatti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶L.Mangiagalli Obstetric Clinic, IRCSS Cà Granda, Ospedale Maggiore of Milano, Milano, Italy, ⁷Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milano, Italy
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results From a Multicenter Italian Cohort Over 20 Years Of Experience Background/Purpose: Antiphospholipid antibodies (aPL)…
Abstract Number: 2457 • 2016 ACR/ARHP Annual Meeting
Role of Hydroxychloroquine in Improving Pregnancy Outcomes in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease
Savino Sciascia¹, Simone Baldovino², Dario Roccatello² and Maria Jose Cuadrado³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ³St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Heparins and/or low-dose aspirin represent the treatment of choice for the management of pregnant women with antiphospholipid antibodies (aPL). However, despite these treatments, maternal, fetal, and…
Abstract Number: 2458 • 2016 ACR/ARHP Annual Meeting
Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review
Omid Zahedi Niaki¹, Christian A. Pineau², Sasha Bernatsky^3,4 and Evelyne Vinet³, ¹Université de Montréal, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Given the obvious female predominance of rheumatic diseases, significant attention has already been drawn to the impact of these conditions on female sexual function.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].